Our team

Greg Tanaka serves as Chief AI Officer at Karyon Bio, where he leads the company’s AI and machine learning vision across its F2+ fibrosis care pathway and broader precision-medicine platform.

Greg brings more than two decades of experience building and scaling AI-driven products at the intersection of machine learning, data platforms, and real-world decision systems. He is the Founder and CEO of Percolata, an AI company backed by Google Ventures, Andreessen Horowitz, and Menlo Ventures, where he pioneered large-scale forecasting and analytics platforms using deep learning, computer vision, IoT sensor data, and cloud infrastructure. Percolata’s technology helped global enterprises improve operational efficiency and revenue through high-accuracy predictive models .

Across his career, Greg has led teams spanning machine learning, software, hardware, and product management, with hands-on experience deploying AI systems in production across AWS, GCP, and Azure. His background includes foundational work in imaging, GPUs, and computer vision, as well as multiple patented innovations in data processing and visual monitoring systems.

At Karyon Bio, Greg is responsible for guiding the long-term AI architecture, model strategy, and platform scalability—ensuring that advanced machine learning translates into clinically meaningful, explainable, and deployable solutions for liver disease detection and care pathways. He works closely with leadership and engineering teams to align AI innovation with clinical trust, regulatory readiness, and real-world adoption.

Greg is a UC Berkeley and Caltech alumnus and is also known for his public-service leadership, having served on the Palo Alto City Council. He is passionate about applying AI to solve complex, high-impact problems in healthcare and beyond.

Dr. Robert J. Wong, MD, MS, FACG, FAASLD, is a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine and a staff hepatologist at the Veterans Affairs Palo Alto Health Care System. His clinical practice focuses on complex liver disease, including steatotic liver disease (MASLD/MASH), alcohol-associated liver disease, viral hepatitis and hepatocellular carcinoma, giving him a front-line view of how patients move (or fail to move) through real-world liver care pathways.

Dr. Wong is internationally recognized for his work in liver epidemiology and health-services research. He has led influential studies quantifying the prevalence and predictors of hepatic fibrosis in NAFLD, the comorbidity and cost burden of NASH with advanced liver disease, and the changing etiologies of patients awaiting liver transplantation in the United States. His recent review on the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease provides a comprehensive picture of the rising global burden of steatotic liver disease and the cardiometabolic and behavioral drivers behind it. He has also developed decision-support tools and studied real-world gaps in HCC surveillance and hepatitis B/Delta testing, directly connecting data to actionable improvements in care delivery.

As Chief Clinical Scientist at Karyon Bio, Dr. Wong’s expertise sits right at the intersection of what matters for LiverTwin™: identifying who is truly at risk for F2+ fibrosis, understanding how they are (and are not) being captured in current systems, and designing interventions that are clinically credible and operationally realistic. His work on fibrosis prevalence, advanced disease outcomes, transplant trends and health-care utilization helps Karyon focus its multimodal F2+ risk engines on the populations and care gaps that actually drive cirrhosis, liver cancer and cost. In this role, he leads the clinical science strategy for LiverTwin™, shaping triage thresholds, validation study design and hospital collaboration strategy so that our F2+ triage and notification pathways are not just scientifically rigorous, but also deployable in hepatology, VA, safety-net and integrated health systems worldwide.